Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. We believe
Location: United States, Pennsylvania, West Chester
Employees: 11-50
Total raised: $180M
Founded date: 2013
Investors 3
| Date | Name | Website |
| - | PBM Capita... | pbmcap.com |
| 30.08.2023 | OrbiMed | orbimed.co... |
| - | Pharus Cap... | pharus.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 26.07.2023 | - | $125M | OrbiMed |
| 11.03.2020 | - | $55M | - |
Mentions in press and media 17
| Date | Title | Description |
| 11.11.2025 | Lytix Biopharma Announces Promising Interim Data on Neoadjuvant Treatment of Melanoma with Ruxotemitide from the NeoLIPA Study at the Norwegian Radium Hospital | Lytix Biopharma Announces Promising Interim Data on Neoadjuvant Treatment of Melanoma with Ruxotemitide from the NeoLIPA Study at the Norwegian Radium Hospital Tue, Nov 11, 2025 07:00 CET Report this content Investigator-assessed pathologic... |
| 10.11.2025 | New Phase II Study Data from Lytix Biopharma’s Partner Presented at SITC 2025 Further Validate Unique Immune-Activating Mechanism of Ruxotemitide | New Phase II Study Data from Lytix Biopharma’s Partner Presented at SITC 2025 Further Validate Unique Immune-Activating Mechanism of Ruxotemitide Mon, Nov 10, 2025 07:00 CET Report this content Oslo, Norway, November 10, 2025 – Lytix Biopha... |
| 28.08.2025 | Lytix Biopharma Q2/H1 2025: Preparing for a milestone-rich second half with advancing clinical programs and strengthened organization | Lytix Biopharma Q2/H1 2025: Preparing for a milestone-rich second half with advancing clinical programs and strengthened organization Thu, Aug 28, 2025 07:07 CET Report this content Oslo, Norway, August 28, 2025 – Lytix Biopharma AS, a clin... |
| 22.01.2025 | Lytix Biopharma AS – Licensing partner Verrica Pharmaceuticals presents clinical data with LTX-315 at the 2025 Winter Clinical Dermatology Conference | Lytix Biopharma AS – Licensing partner Verrica Pharmaceuticals presents clinical data with LTX-315 at the 2025 Winter Clinical Dermatology Conference Wed, Jan 22, 2025 08:05 CET Report this content Oslo, Norway, January 22, 2025 – Lytix Bio... |
| 21.11.2024 | Lytix Biopharma – Licensing partner Verrica Pharmaceuticals announces pricing of underwritten public offering, raising approximately USD 42 million upon completion | Lytix Biopharma – Licensing partner Verrica Pharmaceuticals announces pricing of underwritten public offering, raising approximately USD 42 million upon completion Thu, Nov 21, 2024 15:48 CET Report this content Oslo, November 21st 2024: Ly... |
| 05.11.2024 | Lytix Biopharma - Update from licensing partner Verrica Pharmaceuticals | Lytix Biopharma - Update from licensing partner Verrica Pharmaceuticals Tue, Nov 05, 2024 07:05 CET Report this content Oslo, November 5th, 2024: Lytix Biopharma, a Norwegian immuno-oncology company dedicated to being part of tomorrow’s can... |
| 24.10.2024 | Lytix Biopharma Highlights Positive Data on LTX-315 in Collaboration with Verrica Pharmaceuticals at 2024 Fall Clinical Dermatology Conference | Lytix Biopharma Highlights Positive Data on LTX-315 in Collaboration with Verrica Pharmaceuticals at 2024 Fall Clinical Dermatology Conference Thu, Oct 24, 2024 14:19 CET Report this content Oslo, Norway, October 24, 2024 - Lytix Biopharma,... |
| 20.08.2024 | New Horizons in Cancer Treatment: Hope on the Horizon | Cancer is a relentless foe. It creeps into lives, turning the ordinary into the extraordinary struggle. But recent advancements in treatment are changing the narrative. New therapies are emerging, offering hope where there was once despair.... |
| 14.08.2024 | PhII preliminary results from skin cancer clinical trial show an 86%overall reduction of tumor size, complete clearance in 51%of the patients and the potential to be utilized as a first-line therapy | PhII preliminary results from skin cancer clinical trial show an 86%overall reduction of tumor size, complete clearance in 51%of the patients and the potential to be utilized as a first-line therapy Wed, Aug 14, 2024 13:44 CET Report this c... |
| 06.08.2024 | Lytix Biopharma: Lytix’s licensing partner, Verrica Pharmaceuticals, to release preliminary topline results from their Phase II trial of LTX-315 for the treatment of basal cell carcinoma on August 14... | Lytix Biopharma: Lytix’s licensing partner, Verrica Pharmaceuticals, to release preliminary topline results from their Phase II trial of LTX-315 for the treatment of basal cell carcinoma on August 14 Tue, Aug 06, 2024 16:51 CET Report this ... |
Show more